NEW YORK–(BUSINESS WIRE)–Rosen Law Firm, a global investor rights law firm, is continuing to
investigate potential securities claims on behalf of shareholders of
Helius Medical Technologies, Inc. (NASDAQ: HSDT) resulting from
allegations that Helius may have issued materially misleading business
information to the investing public.
On January 22, 2019, White Diamond Research published an article stating
that Helius’ phase III trial “missed its primary effectiveness endpoint”
and that Helius “has redacted important trial info.” The article further
states that the founders “have a history of questionable marketing
practices” and that the former CEO “is now a fugitive.” On this news,
shares of Helius fell $0.97 or over 11.6% over the next two trading days
to close at $7.36 on January 23, 2019.
Rosen Law Firm is preparing a class action lawsuit to recover losses
suffered by Helius investors. If you purchased shares of Helius please
visit the firm’s website at https://www.rosenlegal.com/cases-1496.html
to join the class action. You may also contact Phillip Kim or Zachary
Halper of Rosen Law Firm toll free at 866-767-3653 or via email at firstname.lastname@example.org
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm,
on Twitter: https://twitter.com/rosen_firm
or on Facebook: https://www.facebook.com/rosenlawfirm/.
Rosen Law Firm represents investors throughout the globe, concentrating
its practice in securities class actions and shareholder derivative
litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class
Action Services for number of securities class action settlements in
2017. The firm has been ranked in the top 3 each year since 2013.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Laurence Rosen, Esq.
Phillip Kim, Esq.
Zachary Halper, Esq.
Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653